Lower-intensity treatment is appropriate for patients who are not candidates for intensive induction or when disease biology and patient factors favor a non-intensive approach. Selection should consider molecular profile, cytopenias, infection risk, organ function, drug interactions, ability to attend frequent monitoring, transfusion support, and goals of care.
-
Favorable or intermediate-risk AML
For lower-intensity candidates with favorable or intermediate-risk AML, HMA plus venetoclax is a common preferred approach when clinically appropriate. Monitor carefully for prolonged cytopenias, infections, tumor lysis risk, and need for venetoclax schedule modification after response.
-
HMA + venetoclax-based approach
HMA + venetoclax is a preferred lower-intensity approach for many patients with newly diagnosed AML who are not candidates for intensive induction. Implementation caveats: - Assess tumor lysis risk and infection risk before starting. - Monitor closely for prolonged cytopenias and infectious complications. - Bone marrow assessment around day 14–21, often day 21, can help guide venetoclax duration and schedule. - Venetoclax duration may need to be shortened based on marrow cellularity, blast clearance, count recovery, cytopenias, infection risk, and molecular profile. - After remission or marrow aplasia, venetoclax schedule adjustment is often needed to reduce prolonged cytopenias. This is particularly important when using HMA + venetoclax as frontline lower-intensity therapy.
-
Day 14–21 marrow assessment for HMA + venetoclax
For patients receiving HMA + venetoclax, consider bone marrow assessment around day 14–21, often day 21, to evaluate blast clearance and marrow cellularity. This assessment can guide:- Venetoclax duration in cycle 1- Need for treatment hold- Timing of next cycle- Growth factor consideration when appropriate- Cytopenia management- Infection-risk mitigation- Subsequent venetoclax schedule shortening Venetoclax duration should be individualized based on marrow cellularity, residual disease, count recovery, cytopenias, infections, molecular profile, and overall clinical status.
-
Response assessment / MRD when applicable
Assess response after induction using marrow assessment, count recovery, cytogenetics/molecular markers, and MRD when applicable. Response assessment should inform consolidation, transplant referral, maintenance planning, or transition to relapsed/refractory strategy.
-
Proceed to consolidation / post-remission algorithm
Patients achieving remission or meaningful response should proceed to a consolidation / post-remission strategy based on genetic risk, MRD status, induction regimen, fitness, donor availability, and transplant eligibility.
-
IDH1-mutant AML
For lower-intensity candidates with IDH1-mutated AML, consider azacitidine plus venetoclax or azacitidine plus ivosidenib when clinically appropriate. Selection should consider disease tempo, differentiation syndrome risk, QT risk, cytopenias, drug interactions, access, and patient goals.
-
IDH2-mutated AML
For lower-intensity candidates with IDH2-mutated AML, azacitidine plus venetoclax is commonly used. IDH2 inhibitor-based approaches may be considered in selected patients depending on availability, prior therapy, disease tempo, toxicity profile, and expert review. Important caveat: Upfront IDH2 inhibitor combination strategies remain investigational and should preferably be used in the context of a clinical trial or expert-guided setting.
-
FLT3-mutated AML
For lower-intensity candidates with FLT3-mutated AML, HMA plus venetoclax is commonly used, but responses may be less durable and relapse risk is high. Consider FLT3 inhibitor strategy or targeted clinical trial when available, especially for FLT3-ITD disease.
-
HMA + venetoclax-based approach
HMA + venetoclax is a preferred lower-intensity approach for many patients with newly diagnosed AML who are not candidates for intensive induction. Implementation caveats: - Assess tumor lysis risk and infection risk before starting. - Monitor closely for prolonged cytopenias and infectious complications. - Bone marrow assessment around day 14–21, often day 21, can help guide venetoclax duration and schedule. - Venetoclax duration may need to be shortened based on marrow cellularity, blast clearance, count recovery, cytopenias, infection risk, and molecular profile. - After remission or marrow aplasia, venetoclax schedule adjustment is often needed to reduce prolonged cytopenias. This is particularly important when using HMA + venetoclax as frontline lower-intensity therapy.
-
Secondary / therapy-related AML, MRC (non-TP53)
For therapy-related AML, secondary AML, or AML with myelodysplasia-related features without TP53/17p alteration, CPX-351 is an important intensive option in appropriate patients. Evidence note:CPX-351 improved overall survival compared with conventional 7+3 in older patients with high-risk secondary AML, including therapy-related AML and AML with myelodysplasia-related changes. Treatment choice should still be individualized based on age, fitness, organ function, disease biology, access, and transplant strategy.
-
HMA + venetoclax-based approach
HMA + venetoclax is a preferred lower-intensity approach for many patients with newly diagnosed AML who are not candidates for intensive induction. Implementation caveats: - Assess tumor lysis risk and infection risk before starting. - Monitor closely for prolonged cytopenias and infectious complications. - Bone marrow assessment around day 14–21, often day 21, can help guide venetoclax duration and schedule. - Venetoclax duration may need to be shortened based on marrow cellularity, blast clearance, count recovery, cytopenias, infection risk, and molecular profile. - After remission or marrow aplasia, venetoclax schedule adjustment is often needed to reduce prolonged cytopenias. This is particularly important when using HMA + venetoclax as frontline lower-intensity therapy.
-
Day 14–21 marrow assessment for HMA + venetoclax
For patients receiving HMA + venetoclax, consider bone marrow assessment around day 14–21, often day 21, to evaluate blast clearance and marrow cellularity. This assessment can guide:- Venetoclax duration in cycle 1- Need for treatment hold- Timing of next cycle- Growth factor consideration when appropriate- Cytopenia management- Infection-risk mitigation- Subsequent venetoclax schedule shortening Venetoclax duration should be individualized based on marrow cellularity, residual disease, count recovery, cytopenias, infections, molecular profile, and overall clinical status.
-
Response assessment / MRD when applicable
Assess response after induction using marrow assessment, count recovery, cytogenetics/molecular markers, and MRD when applicable. Response assessment should inform consolidation, transplant referral, maintenance planning, or transition to relapsed/refractory strategy.
-
Proceed to consolidation / post-remission algorithm
Patients achieving remission or meaningful response should proceed to a consolidation / post-remission strategy based on genetic risk, MRD status, induction regimen, fitness, donor availability, and transplant eligibility.
-
TP53-mutated or 17p deletion
TP53-mutated AML or AML with 17p deletion has very high-risk biology and poor outcomes with available standard approaches. Clinical trial is preferred whenever available. Key implementation caveats: - Intensive chemotherapy is often not clearly superior to non-intensive therapy in this subgroup. - HMA + venetoclax has not clearly overcome the adverse prognosis of TP53-mutated AML. - Early goals-of-care discussion, transplant feasibility assessment, infection/supportive care planning, and clinical trial consideration are essential. - Treatment selection should be individualized based on fitness, symptoms, cytopenias, disease tempo, patient goals, and trial access. Relevant references should include the TP53-mutated AML literature suggested by the lead author.